NCT03797872View on ClinicalTrials.gov

Psoriatic Oligoarthritis Intervention With Symptomatic thErapy

PHASE4CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

July 16, 2020

Study Completion Date

July 16, 2020

Conditions
Psoriatic Arthritis
Interventions
DRUG

Methotrexate

Methotrexate up to 25mg/week as tolerated po or sc

DRUG

Sulfasalazine

Sulfasalazine up to 3g daily po

DRUG

Leflunomide

Leflunomide 10-20mg daily po

DRUG

Methylprednisolone

For IA or IM injection 20-120mg

DRUG

Triamcinolone

For IA or IM injection 20-120mg

Trial Locations (1)

OX3 7LD

Oxford University Hospitals NHS Trust, Oxford

All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

University of Oxford

OTHER

NCT03797872 - Psoriatic Oligoarthritis Intervention With Symptomatic thErapy | Biotech Hunter | Biotech Hunter